NeueHealth, Inc. (NEUE) Q3 2024 Earnings Conference Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary presents a mixed picture: strong consumer growth and solid financial performance, but challenges with ACA insurance wind-down and economic uncertainties. The Q&A section lacks clarity, failing to address concerns adequately. Despite positive EBITDA and revenue growth, the lack of new partnerships or strong guidance adjustments limits positive sentiment. The market may react neutrally over the next two weeks, as strengths are balanced by risks and uncertainties.
Key Financial Performance
Adjusted EBITDA $9.4 million, an increase from previous quarters, marking the company's best quarterly financial performance.
Total Revenue $232.9 million, reflecting strong growth and exceeding expectations.
Gross Margin $50.2 million, contributing to the overall strong financial performance.
Consumers Served Approximately 509,000, representing growth of more than 30% over Q3 2023.
NeueCare Revenue $83.9 million, with operating income of $16.4 million, indicating strong performance in care delivery.
NeueSolutions Revenue $152 million, with an operating loss of $5.8 million due to payments made to NeueCare for ACO Reach participation.
Cash and Investments $242.3 million as of September 30, 2024, with $119.2 million in nonregulated cash and short-term investments.
ACA Insurance Business Cash Approximately $123 million to fund remaining medical costs and wind-down expenses.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Adjusted EBITDA: Generated $9.4 million of adjusted EBITDA in Q3 2024, achieving $17 million for the first three quarters.
Consumer Base Growth: Served approximately 509,000 consumers across NeueCare and NeueSolutions segments, exceeding guidance.
Acquisition of Centrum Health: Acquired full ownership of Centrum Health to streamline operations and enhance value-driven care.
Market Expansion in Central Florida: Expanded footprint in Central Florida, increasing the number of consumers served through owned and affiliated clinics.
Medicaid Population Growth: Identified opportunities to grow the Medicaid population served in partnership with federally qualified health centers.
Operational Efficiency: Achieved adjusted EBITDA profitability for three consecutive quarters, indicating strong operational performance.
Provider Enablement: Continued to deliver solid results in provider enablement, growing the number of consumers served.
Diversification Strategy: Focused on diversifying consumer base across ACA Marketplace, Medicare, and Medicaid.
Performance-Based Arrangements: Tailored population health tools to support providers in performance-based arrangements.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory Issues: The company mentioned ongoing risks associated with the wind down of its ACA insurance business, which includes obligations due under repayment agreements with CMS.
Competitive Pressures: NeueHealth is focused on diversifying its consumer base across various product categories to mitigate adverse impacts from market dynamics.
Supply Chain Challenges: The company is working to streamline operations and simplify its corporate structure, which may indicate challenges in managing its supply chain effectively.
Economic Factors: The company is aware of the economic environment's impact on its performance and is taking steps to limit adverse effects through diversified growth channels.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Adjusted EBITDA: Generated $9.4 million of adjusted EBITDA in Q3 2024, achieving $17 million through the first three quarters, within the full year guidance range of $15 million to $25 million.
Consumer Growth: Served approximately 509,000 consumers across NeueCare and NeueSolutions segments, slightly above the full year guidance range.
Market Diversification: Focused on diversifying consumer base across ACA Marketplace, Medicare, and Medicaid, with an emphasis on growing the Medicaid population.
Capital-efficient Growth: Aiming to drive capital-efficient growth in existing and new markets by leveraging relationships with payer partners.
Provider Relationships: Growing relationships with diverse providers to enhance participation in performance-based arrangements.
Acquisition of Centrum Health: Acquired full ownership of Centrum Health to streamline operations and support value-driven care model.
2024 Adjusted EBITDA Guidance: Expecting adjusted EBITDA to be between $15 million and $25 million.
2024 Revenue Guidance: Expecting consolidated revenue of approximately $950 million, with $320 million from NeueCare and $640 million from NeueSolutions.
Consumer Service Guidance: Anticipating to serve between 475,000 and 500,000 consumers across both segments, with expectations to be at the high end of this range.
Value-based Consumers Guidance: Expecting to serve between 330,000 and 345,000 value-based consumers in clinics and 145,000 to 155,000 in NeueSolutions.
Adjusted Operating Cost Ratio Guidance: Expecting adjusted operating cost ratio to be between 15% and 16%, and 19% to 20% when including corporate costs.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Adjusted EBITDA: $9.4 million in the third quarter, with a total of $17 million for the first three quarters of 2024.
Consolidated Revenue: $232.9 million for the third quarter.
2024 Revenue Guidance: Expected consolidated revenue of approximately $950 million.
Consumer Base: Expected to serve between 475,000 and 500,000 consumers across segments in 2024.
Value-Based Consumers: Expected to serve between 330,000 and 345,000 value-based consumers in clinics.
Cash Position: $242.3 million in total cash and investments as of September 30, 2024.
Shareholder Return Plan: None
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Can you provide more details on the growth of the Medicaid population you serve?
A:We see an opportunity to grow the Medicaid population we serve in partnership with federally qualified health centers and other provider groups.
Q:What specific strategies are you implementing to drive capital-efficient growth?
A:We are leveraging the strong relationships we have formed with our payer partners.
Q:How do you plan to expand your participation in innovative programs like ACO Reach?
A:We are exploring opportunities to expand our participation in innovative programs like ACO Reach and MSSP in the future.
Q:Can you clarify the financial impact of the wind down of your ACA insurance business?
A:We continue to retrieve capital from our discontinued entities, and our remaining liability associated with our ACA insurance business continues to steadily decline.
Q:What are your expectations for consumer growth in 2025?
A:We believe we are well positioned to finish 2024 on a strong note and expect continued success and growth in 2025.
Q:Review of Unclear Management Responses
A:Management did not provide specific details on the strategies for capital-efficient growth or the financial impact of the ACA insurance business wind down.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
ACA insurance
ACO Reach
Assistant Vice
CEO CFO
CFO Ladies
CMS program
Centrum Health
ET Assistant
Federal Securities
Florida number
Health clinic
Health value
Ladies gentleman
Laws statement
MSSP future
Medicaid NeueCare
Medicaid ability
Medicaid population
NeueHealth date
NeueHealth profitability
NeueSolutions result
President Mikan
Reach MSSP
Reach Medicare
Reach NeueSolutions
care delivery
delivery provider
experience consumer
market
number consumer
participation
partner care
program ACO
quarter NeueHealth
relationship payer
success
variety
NEUE Transcript
NeueHealth, Inc. (NYSE:NEUE) Q4 2024 Earnings Call Transcript
Unknown3-22
Despite reporting a strong year of financial performance, the significant EPS miss and lack of a shareholder return plan overshadow positive aspects. The Q&A highlighted growth and profitability in some areas but also revealed challenges and uncertainties, especially in the NeueSolutions segment. The acquisition by NEA may provide long-term benefits, but the immediate impact of the earnings miss and financial instability is likely to result in a negative stock price reaction in the short term.
NeueHealth, Inc (NEUE) Q4 2024 Earnings Call Transcript
Neutral3-20
NeueHealth, Inc (NEUE) Q4 2024 Earnings Call Transcript
Unknown3-20
The earnings call reveals strong financial performance, with revenue and EBITDA growth, and a solid cash position. However, the acquisition announcement and pending transition to a private entity may cause uncertainty. Additionally, management's vague responses in the Q&A, especially regarding supply chain challenges and the new product launch timeline, may concern investors. The acquisition and regulatory risks further temper the positive financial results. Given these mixed signals and the lack of market cap data, a neutral stock price movement is predicted.
NeueHealth, Inc. (NEUE) Q3 2024 Earnings Conference Call Transcript
Unknown11-10
The earnings call summary presents a mixed picture: strong consumer growth and solid financial performance, but challenges with ACA insurance wind-down and economic uncertainties. The Q&A section lacks clarity, failing to address concerns adequately. Despite positive EBITDA and revenue growth, the lack of new partnerships or strong guidance adjustments limits positive sentiment. The market may react neutrally over the next two weeks, as strengths are balanced by risks and uncertainties.
NEUE Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
